blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3541375

EP3541375 - FACTOR XIIA INHIBITORS [Right-click to bookmark this link]
Former [2019/39]FACTOR XIIa INHIBITORS
[2022/44]
StatusNo opposition filed within time limit
Status updated on  27.06.2024
Database last updated on 17.09.2024
FormerThe patent has been granted
Status updated on  21.07.2023
FormerGrant of patent is intended
Status updated on  15.03.2023
FormerExamination is in progress
Status updated on  21.02.2023
FormerGrant of patent is intended
Status updated on  02.11.2022
FormerExamination is in progress
Status updated on  31.03.2022
FormerRequest for examination was made
Status updated on  23.08.2019
FormerThe international publication has been made
Status updated on  25.05.2018
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): SI		published on 04.09.2024  [2024/36]
Applicant(s)For all designated states
Merck Sharp & Dohme LLC
126 East Lincoln Avenue
Rahway, New Jersey 07065 / US
[2022/42]
Former [2019/39]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Inventor(s)01 / RAO, Ashwin, U.
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
02 / MCKITTRICK, Brian Alexander
14 Millbrook Road
New Vernon, New Jersey 07976 / US
03 / LOMBARDO, Matthew
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
04 / HICKS, Jacqueline, D.
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
05 / MCCRACKEN, Amy Bittner
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
06 / CHU, Hong Dong
21 Riker Hill Road
Livingston, New Jersey 07039 / US
07 / SO, Sung-Sau
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
08 / ORTH, Peter
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
09 / WU, Zhicai
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
10 / LAN, Ping
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
11 / DEBENHAM, John, S.
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
12 / WHITEHEAD, Brent, R.
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
13 / TAYLOR, Jerry, A.
40 Division Street
Trenton, New Jersey 08611 / US
14 / SUN, Zhongxiang
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
15 / KATIPALLY, Revathi Reddy
23 Potomac Road
Monmouth, New Jersey 08852 / US
16 / GABLE, Jonathan, E.
120 West 45th Street
17th Floor
New York, New York 10036 / US
17 / DAHLGREN, Markus, K.
120 West 45th Street
17th Floor
New York, New York 10036 / US
18 / BHAT, Sathesh, P.
120 West 45th Street
17th Floor
New York, New York 10036 / US
 [2019/39]
Representative(s)Merck Sharp & Dohme LLC
120 Moorgate
London EC2M 6UR / GB
[2023/34]
Former [2019/39]Jaap, David Robert
MSD
Hertford Road
Hoddesdon, Herts EN11 9BU / GB
Application number, filing date17872824.213.11.2017
[2019/39]
WO2017US61222
Priority number, dateUS201662423844P18.11.2016         Original published format: US 201662423844 P
[2019/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018093695
Date:24.05.2018
Language:EN
[2018/21]
Type: A1 Application with search report 
No.:EP3541375
Date:25.09.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 24.05.2018 takes the place of the publication of the European patent application.
[2019/39]
Type: B1 Patent specification 
No.:EP3541375
Date:23.08.2023
Language:EN
[2023/34]
Search report(s)International search report - published on:US24.05.2018
(Supplementary) European search report - dispatched on:EP14.04.2020
ClassificationIPC:A61K31/395, A61K31/495, A61K31/4965, C07D241/00, C07D241/02, C07D241/04, A61K45/06, A61P7/02, // C07D403/12, C07D409/12, C07D409/14, C07D413/04, C07D413/14, C07D495/04, A61P15/00
[2022/44]
CPC:
A61K45/06 (EP); C07D413/14 (EP,US); A61P7/02 (EP,US);
C07D241/04 (EP); C07D403/12 (EP); C07D409/12 (EP);
C07D409/14 (EP); C07D413/04 (EP); C07D495/04 (EP,US) (-)
Former IPC [2020/20]A61K31/395, A61K31/495, A61K31/4965, C07D241/00, C07D241/02, C07D241/04, // C07D403/12, C07D409/12, C07D409/14, C07D413/04, C07D413/14, C07D495/04, A61P15/00
Former IPC [2019/39]A61K31/395, A61K31/495, A61K31/4965, C07D241/00, C07D241/02, C07D241/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/39]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:FAKTOR XIIA INHIBITOREN[2022/44]
English:FACTOR XIIA INHIBITORS[2022/44]
French:INHIBITEURS DU FACTEUR XIIA[2019/39]
Former [2019/39]FAKTOR-XIIA-INHIBITOREN
Former [2019/39]FACTOR XIIa INHIBITORS
Entry into regional phase18.06.2019National basic fee paid 
18.06.2019Search fee paid 
18.06.2019Designation fee(s) paid 
18.06.2019Examination fee paid 
Examination procedure18.06.2019Examination requested  [2019/39]
06.11.2020Amendment by applicant (claims and/or description)
30.03.2022Despatch of a communication from the examining division (Time limit: M02)
27.05.2022Reply to a communication from the examining division
03.11.2022Communication of intention to grant the patent
20.02.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
16.03.2023Communication of intention to grant the patent
10.07.2023Fee for grant paid
10.07.2023Fee for publishing/printing paid
12.07.2023Receipt of the translation of the claim(s)
Opposition(s)24.05.2024No opposition filed within time limit [2024/31]
Fees paidRenewal fee
14.11.2019Renewal fee patent year 03
10.11.2020Renewal fee patent year 04
08.11.2021Renewal fee patent year 05
10.11.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT23.08.2023
CZ23.08.2023
DK23.08.2023
EE23.08.2023
ES23.08.2023
FI23.08.2023
HR23.08.2023
IT23.08.2023
LT23.08.2023
LV23.08.2023
MC23.08.2023
NL23.08.2023
PL23.08.2023
RO23.08.2023
RS23.08.2023
SE23.08.2023
SI23.08.2023
SK23.08.2023
SM23.08.2023
LU13.11.2023
NO23.11.2023
GR24.11.2023
CH30.11.2023
IS23.12.2023
PT26.12.2023
[2024/36]
Former [2024/34]AT23.08.2023
CZ23.08.2023
DK23.08.2023
EE23.08.2023
ES23.08.2023
FI23.08.2023
HR23.08.2023
IT23.08.2023
LT23.08.2023
LV23.08.2023
MC23.08.2023
NL23.08.2023
PL23.08.2023
RO23.08.2023
RS23.08.2023
SE23.08.2023
SK23.08.2023
SM23.08.2023
LU13.11.2023
NO23.11.2023
GR24.11.2023
CH30.11.2023
IS23.12.2023
PT26.12.2023
Former [2024/32]AT23.08.2023
CZ23.08.2023
DK23.08.2023
EE23.08.2023
ES23.08.2023
FI23.08.2023
HR23.08.2023
IT23.08.2023
LT23.08.2023
LV23.08.2023
MC23.08.2023
NL23.08.2023
PL23.08.2023
RO23.08.2023
RS23.08.2023
SE23.08.2023
SK23.08.2023
SM23.08.2023
NO23.11.2023
GR24.11.2023
IS23.12.2023
PT26.12.2023
Former [2024/26]AT23.08.2023
CZ23.08.2023
DK23.08.2023
EE23.08.2023
ES23.08.2023
FI23.08.2023
HR23.08.2023
IT23.08.2023
LT23.08.2023
LV23.08.2023
NL23.08.2023
PL23.08.2023
RO23.08.2023
RS23.08.2023
SE23.08.2023
SK23.08.2023
SM23.08.2023
NO23.11.2023
GR24.11.2023
IS23.12.2023
PT26.12.2023
Former [2024/23]AT23.08.2023
CZ23.08.2023
DK23.08.2023
EE23.08.2023
ES23.08.2023
FI23.08.2023
HR23.08.2023
LT23.08.2023
LV23.08.2023
NL23.08.2023
PL23.08.2023
RO23.08.2023
RS23.08.2023
SE23.08.2023
SK23.08.2023
SM23.08.2023
NO23.11.2023
GR24.11.2023
IS23.12.2023
PT26.12.2023
Former [2024/22]AT23.08.2023
CZ23.08.2023
DK23.08.2023
FI23.08.2023
HR23.08.2023
LT23.08.2023
LV23.08.2023
NL23.08.2023
PL23.08.2023
RO23.08.2023
RS23.08.2023
SE23.08.2023
SM23.08.2023
NO23.11.2023
GR24.11.2023
IS23.12.2023
PT26.12.2023
Former [2024/20]AT23.08.2023
FI23.08.2023
HR23.08.2023
LT23.08.2023
LV23.08.2023
NL23.08.2023
PL23.08.2023
RS23.08.2023
SE23.08.2023
SM23.08.2023
NO23.11.2023
GR24.11.2023
IS23.12.2023
PT26.12.2023
Former [2024/10]AT23.08.2023
FI23.08.2023
HR23.08.2023
LT23.08.2023
LV23.08.2023
NL23.08.2023
PL23.08.2023
RS23.08.2023
SE23.08.2023
NO23.11.2023
GR24.11.2023
IS23.12.2023
PT26.12.2023
Former [2024/09]AT23.08.2023
FI23.08.2023
LT23.08.2023
NL23.08.2023
SE23.08.2023
NO23.11.2023
GR24.11.2023
IS23.12.2023
Former [2024/08]LT23.08.2023
NL23.08.2023
NO23.11.2023
GR24.11.2023
Documents cited:Search[A]WO9857960  (SCHERING CORP [US], et al) [A] 1-11* page 4, line 5 - page 4, line 13; claim -; compound 246 *;
 [A]WO2006113376  (NOVARTIS AG [CH], et al) [A] 1-11 * paragraph [0001]; compounds 65,70,73,82,88 *;
 [X]WO2008016676  (CYTOKINETICS INC [US], et al) [X] 1 * page 75, 1st compound; paragraph [0002] *
International search[A]US2008003214  (CEZANNE BERTRAM [DE], et al) [A] 1-6, 8-16 * entire document *;
 [A]US2008287453  (BOWER JUSTIN FAIRFIELD [GB], et al) [A] 1-6, 8-16 * entire document' *;
 [A]US2011033459  (CONLEY PAMELA B [US], et al) [A] 1-6, 8-16* entire document *
by applicantUS2008003214
 US2011033459
    - SHARIAT-MADAR et al., Blood, (20060000), vol. 108, pages 192 - 199
    - "Contact ActivationPathway", COLEMAN, R., Hemostasis and Thrombosis, Lippincott Williams & Wilkins, (20010000), pages 103 - 122
    - SCHMAIER, A.H., "Contact Activation", Thrombosis and Hemorrhage, (19980000), pages 105 - 128
    - RENNE et al., J Exp. Med., (20050000), vol. 202, pages 271 - 281
    - KLEINSCHMITZ et al., J Exp. Med., (20060000), vol. 203, pages 513 - 518
    - KENNE, E.RENNE, T., "Factor XII: a drug target for safe interference with thrombosis and inflammation", Drug DISCOvery Today, (20140000), vol. 19, pages 1459 - 146
    - RENNE, T. et al., "In vivo roles of factor XII", Blood, (20120000), vol. 120, doi:10.1182/blood-2012-, pages 4296 - 4303, XP055599576

DOI:   http://dx.doi.org/10.1182/blood-2012-
    - KLEINSCHNITZ, C. et al., "Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis", Journal of Experimental Medicine, (20060000), vol. 203, doi:10.1084/jem.20052458, pages 513 - 518, XP055110912

DOI:   http://dx.doi.org/10.1084/jem.20052458
    - GRUBER, A. et al., Therapeutic antibodies against factor XII, Vanderbilt University, (20140000), page 91
    - WORM, M. et al., "The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti inflammatory activities", Annals of Translational Medicine, (20150000), vol. 3, pages 241 - 245
    - CHENG, Q.TUCKER, E. I.PINE, M. S.SISLER, I.MATAFONOV, A.SUN, M.-F.WHITE-ADAMS, T. C.SMITH, S. A.HANSON, S. R.MCCARTY, O. J. T., "A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo", Blood, (20100000), vol. 116, doi:10.1182/blood-2010-02-270918, pages 3981 - 3989, XP055355312

DOI:   http://dx.doi.org/10.1182/blood-2010-02-270918
    - GAILANI, D. et al., "Factor XI and contact activation as targets for antithrombotic therapy", Journal of Thrombosis andHaemostasis, (20150000), vol. 13, pages 1383 - 1395
    - CHOUTALALAY, Adv. Enzyme Regul., (19840000), vol. 22, pages 27 - 55
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.